Evaluation of drug-drug interactions and side effects in COVID-19 patients in an intensive care unit

Basit Öğe Kaydı
dc.authorid0000-0002-6141-8676
dc.authorid0000-0002-7636-1393
dc.authorid0000-0001-6587-8103
dc.authorid0000-0002-5715-8138
dc.contributor.authorTaner, Neda
dc.contributor.authorŞirin, Betül
dc.contributor.authorKızılaslan, Deniz
dc.contributor.authorErdoğan, Cem
dc.date.accessioned2022-12-09T06:23:02Z
dc.date.available2022-12-09T06:23:02Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Klinik Eczacılık Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Anesteziyoloji ve Reanimasyon Ana Bilim Dalı
dc.description.abstractBACKGROUND/AIM: Considering comorbidity rates in patients diagnosed with coronavirus disease 2019 (COVID-19), polypharmacy will be inevitable when the treatment for COVID-19 is added to the treatment of existing chronic disease conditions. In our study, we evaluated the effects of comorbidities, drug-drug interactions and complications on the clinical course of the disease in COVID-19 patients. MATERIALS AND METHODS: This study was conducted retrospectively with thirty five COVID-19 patients of various age and gender groups who had been admitted to the intensive care unit in a university hospital in March and April, 2020. The demographic, laboratory and clinical data were collected. RESULTS: In our study, the average number of days intubated in patients with acute respiratory distress syndrome and sepsis was found to be statistically significantly higher than those without complications. serious-use alternative interaction was detected in 85.7% of the patients, monitor closely interaction in 60%, and minor interaction in 34.3%. In 88.6% of the patients, at least one of these interactions was observed, while all three interactions occurred at the same time in 20% of them. CONCLUSION: According to the results of this study, managing the risks, interventions such as drug dosage adjustment, and drug changes and monitoring of any parameters that may indicate drug side effects for the patient may be necessary.
dc.identifier.citationTaner, N., Şirin, B., Kızılaslan, D. ve Erdoğan, C. (2022). Evaluation of drug-drug interactions and side effects in COVID-19 patients in an intensive care unit. Cyprus Journal of Medical Sciences, 7(2), 167-174. https://doi.org/10.4274/cjms.2021.2021-4
dc.identifier.doi10.4274/cjms.2021.2021-4
dc.identifier.endpage174
dc.identifier.issn2149-7893
dc.identifier.issn2536-507X
dc.identifier.issue2
dc.identifier.startpage167
dc.identifier.urihttps://doi.org/10.4274/cjms.2021.2021-4
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10096
dc.identifier.volume7
dc.identifier.wos000886750700003en_US
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorTaner, Neda
dc.institutionauthorŞirin, Betül
dc.institutionauthorKızılaslan, Deniz
dc.institutionauthorErdoğan, Cem
dc.language.isoen
dc.publisherGalenos Publishing House
dc.relation.ispartofCyprus Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectIntensive Care Unit
dc.subjectDrug-Drug Interactions
dc.subjectComorbidities
dc.subjectComplications
dc.titleEvaluation of drug-drug interactions and side effects in COVID-19 patients in an intensive care unit
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Taner-Neda-2022.pdf
Boyut:
387.38 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Eczacılık Fakültesi Makale Koleksiyonu
Makale Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu